Advanced glycation end products, oxidant stress and vascular lesions

The formation of advanced glycation end products (AGEs) is observed in conditions such as diabetes mellitus and ageing, both associated with vascular disorders. AGEs form by the interaction of an aldose with NH2 of proteins, and the subsequent Amadori rearrangement leads to complex molecules. The heterogeneous class of AGE molecules is found in plasma, cells and tissues and accumulates in the vessel wall and the kidney. AGE reactions can generate reactive oxygen intermediates (ROIs), which can act as signal mediators and can be deleterious for molecules or cells. The AGEs and ROI‐induced cellular dysfunctions can interfere with the gene expression of peptides and cytokines regulating cell proliferation and vascular functions. The interaction of AGEs with the AGE receptor (RAGE) is followed by a series of intracellular modifications that may be involved in the development of atherosclerosis. An attempt to minimize AGE formation and to limit ROI production by an appropriate therapy may result in the reduction or slowing of vascular disease in patients with diabetes mellitus.

[1]  A. Schmidt,et al.  Endothelial cell dysfunction secondary to the adhesion of diabetic erythrocytes. Modulation by iloprost. , 1996, International angiology : a journal of the International Union of Angiology.

[2]  P. Guillausseau,et al.  Rapid Publication , 1971, Nature.

[3]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[4]  Yong Ming Li,et al.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.

[5]  J. Zweier,et al.  Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide , 1995, Nature Medicine.

[6]  T. Koschinsky,et al.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[7]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[8]  R. Bucala,et al.  Identification of N2-(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. , 1995, Biochemistry.

[9]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[10]  R. O’Brien,et al.  The role of oxidation and glycation in the pathogenesis of diabetic atherosclerosis , 1994, Trends in Endocrinology & Metabolism.

[11]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  G. Lutty,et al.  Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. , 1994, The Journal of biological chemistry.

[13]  G. Striker,et al.  Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Ikemura,et al.  Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. , 1994, Genomics.

[15]  H. Vlassara Recent progress on the biologic and clinical significance of advanced glycosylation end products. , 1994, The Journal of laboratory and clinical medicine.

[16]  M. Simionescu,et al.  The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. , 1994, The Journal of biological chemistry.

[17]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[18]  S. Bursell,et al.  Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. , 1994, Annual review of medicine.

[19]  M. Suthanthiran,et al.  Advanced glycosylation endproduct-specific receptors on human and rat T- lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling , 1993, The Journal of experimental medicine.

[20]  P. Mcclelland,et al.  Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus. , 1993, Clinical science.

[21]  R. Alexander,et al.  Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. , 1993, The Journal of clinical investigation.

[22]  A. Cerami,et al.  Mechanism of Inhibition of Advanced Glycosylation by Aminoguanidine in Vitro , 1993 .

[23]  M. Huijberts,et al.  Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. , 1993, The Journal of clinical investigation.

[24]  B. Ames,et al.  Oxidants, antioxidants, and the degenerative diseases of aging. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Bucala,et al.  Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  N. Morisaki,et al.  Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells. , 1993, Biochemical and biophysical research communications.

[27]  A. Schmidt,et al.  Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. , 1993, The Journal of clinical investigation.

[28]  J. V. Hunt,et al.  Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. , 1993, The Biochemical journal.

[29]  A. Gugliucci,et al.  Polyclonal immunoglobulin M: location of glycation sites. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[30]  S. Krungkrai,et al.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Brownlee,et al.  Glycation Products and the Pathogenesis of Diabetic Complications , 1992, Diabetes Care.

[32]  L. Mandarino Current Hypotheses for the Biochemical Basis of Diabetic Retinopathy , 1992, Diabetes Care.

[33]  J. Baynes,et al.  Role of Oxygen in Cross-Linking and Chemical Modification of Collagen by Glucose , 1992, Diabetes.

[34]  Martina,et al.  Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.

[35]  E. Tsilibary,et al.  Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. , 1992, The Journal of biological chemistry.

[36]  J. Baynes,et al.  Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. , 1992, Archives of biochemistry and biophysics.

[37]  G. Striker,et al.  Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[39]  T. E. Whitaker,et al.  Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. , 1992, The Journal of biological chemistry.

[40]  H. Hammes,et al.  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Green,et al.  Nonenzymatic glycation of platelet proteins in diabetic patients. , 1991, Seminars in thrombosis and hemostasis.

[42]  G. Davı̀,et al.  In Vivo Platelet Activation in Diabetes Mellitus , 1991, Seminars in thrombosis and hemostasis.

[43]  Z. Makita,et al.  Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.

[44]  M. Suthanthiran,et al.  Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.

[45]  Erkki Ruoslahti,et al.  Proteoglycans as modulators of growth factor activities , 1991, Cell.

[46]  J. Oram,et al.  Nonenzymatic Glycosylation of HDL and Impaired HDL-Receptor–Mediated Cholesterol Efflux , 1991, Diabetes.

[47]  K. Tracey,et al.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.

[48]  E. Cagliero,et al.  Characteristics and Mechanisms of High-Glucose–Induced Overexpression of Basement Membrane Components in Cultured Human Endothelial Cells , 1991, Diabetes.

[49]  E. Tsilibary,et al.  Laminin Alterations After In Vitro Nonenzymatic Glycosylation , 1990, Diabetes.

[50]  E. Cagliero,et al.  Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[51]  L. Moldawer,et al.  Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. , 1989, The Journal of clinical investigation.

[52]  H. Gerlach,et al.  Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.

[53]  R. Dean,et al.  Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.

[54]  A. Cerami,et al.  Novel Pyrroles from Sulfite-Inhibited Maillard Reactions: Insight into the Mechanism of Inhibition. , 1988 .

[55]  E. Cagliero,et al.  Increased expression of basement membrane components in human endothelial cells cultured in high glucose. , 1988, The Journal of clinical investigation.

[56]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[57]  A. Cerami,et al.  Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products. , 1988, Archives of biochemistry and biophysics.

[58]  A. Cerami,et al.  Specific Macrophage Receptor Activity for Advanced Glycosylation End Products Inversely Correlates With Insulin Levels In Vivo , 1988, Diabetes.

[59]  M. Bryszewska,et al.  Association between the glycation of erythrocyte membrane proteins and membrane fluidity. , 1988, Clinical biochemistry.

[60]  F. G. NjorogeS,et al.  Mechanism of Formation of the Putative Advanced Glycosylation End , 1988 .

[61]  A. Mosca,et al.  Glycated proteins in serum: effect of their relative proportions on their alkaline reducing activity in the fructosamine test. , 1987, Clinical chemistry.

[62]  C. Kilo,et al.  Increased Vascular Permeability in Spontaneously Diabetic BB/W Rats and in Rats With Mild Versus Severe Streptozocin-Induced Diabetes: Prevention by Aldose Reductase Inhibitors and Castration , 1987, Diabetes.

[63]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[64]  S. Ranganathan,et al.  Metabolism of glycosylated very-low-density lipoproteins in human skin fibroblasts. , 1986, Biochimica et biophysica acta.

[65]  A. Cerami,et al.  High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Rosa,et al.  Clinical manifestations and erythrocyte adhesion to endothelium in sickle cell syndrome , 1985, American journal of hematology.

[67]  R. Nagel,et al.  Membrane knobs are required for the microcirculatory obstruction induced by Plasmodium falciparum-infected erythrocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Widness,et al.  Nonenzymatic Glycosylation of Erythrocytic Proteins in Normal and Diabetic Subjects: Enzymes of Nucleoside and Nucleotide Metabolism , 1985, Diabetes.

[69]  J. Elion,et al.  Evidence for nonenzymic glycation of antithrombin III in diabetic patients. , 1985, Clinical chemistry.

[70]  M. Bryszewska,et al.  Nonenzymatic protein glycosylation. I. Lowered erythrocyte membrane fluidity in juvenile diabetes. , 1985, Annals of clinical research.

[71]  S. Pongor,et al.  Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[72]  V. Monnier,et al.  Accelerated age-related browning of human collagen in diabetes mellitus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Witztum,et al.  A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins. , 1983, The Journal of clinical investigation.

[74]  A. Michael,et al.  Polyantigenic Expansion of Basement Membrane Constituents in Diabetic Nephropathy , 1983, Diabetes.

[75]  M. Sunday Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus. , 1981, The New England journal of medicine.

[76]  P. Higgins,et al.  Reaction of monosaccharides with proteins: possible evolutionary significance. , 1981, Science.

[77]  M. Bitensky,et al.  Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Miller,et al.  Nonenzymatic glycosylation of erythrocyte membrane proteins. Relevance to diabetes. , 1980, The Journal of clinical investigation.

[79]  R. Mahley,et al.  Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins. , 1979, The Journal of clinical investigation.

[80]  P. Gallop,et al.  Structural heterogeneity of human hemoglobin A due to nonenzymatic glycosylation. , 1979, The Journal of biological chemistry.

[81]  H. Bunn,et al.  Functional properties of the glycosylated minor components of human adult hemoglobin. , 1979, The Journal of biological chemistry.

[82]  D. McMillan,et al.  Reduced Erythrocyte Deformability in Diabetes , 1978, Diabetes.

[83]  L. Maillard,et al.  Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .